Heartflow (NASDAQ:HTFL) Given New $68.00 Price Target at Robert W. Baird

Heartflow (NASDAQ:HTFL) had its target price increased by stock analysts at Robert W. Baird from $56.00 to $68.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird‘s price target points to a potential upside of 13.48% from the company’s previous close.

Other equities research analysts have also issued reports about the company. Benchmark reiterated a “buy” rating on shares of Heartflow in a report on Friday, August 14th. JPMorgan Chase & Co. increased their price objective on Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Morgan Stanley raised their price objective on shares of Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. Wells Fargo & Company lifted their target price on shares of Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Finally, Piper Sandler reissued an “overweight” rating and issued a $64.00 target price (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $51.50.

Heartflow Price Performance

HTFL opened at $59.92 on Friday. The stock has a fifty day moving average price of $51.93 and a 200 day moving average price of $35.14. Heartflow has a 1 year low of $20.13 and a 1 year high of $60.65.

Heartflow (NASDAQ:HTFL) last issued its earnings results on Thursday, November 12th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The company had revenue of $72.86 million for the quarter. During the same period in the previous year, the company earned ($0.27) earnings per share. Research analysts expect that Heartflow will post -0.75 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Vikram Verghese sold 29,714 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $50.06, for a total transaction of $1,487,482.84. Following the transaction, the chief financial officer owned 184,789 shares of the company’s stock, valued at approximately $9,250,537.34. This represents a 13.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 23,933 shares of the firm’s stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $55.01, for a total value of $1,316,554.33. Following the completion of the transaction, the insider directly owned 73,453 shares in the company, valued at $4,040,649.53. The trade was a 24.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 332,403 shares of company stock valued at $16,602,786. Insiders own 7.70% of the company’s stock.

Institutional Trading of Heartflow

Several large investors have recently modified their holdings of HTFL. GAMMA Investing LLC grew its stake in Heartflow by 75.1% in the 3rd quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock valued at $32,000 after buying an additional 275 shares during the last quarter. Allworth Financial LP raised its holdings in Heartflow by 116.4% in the 3rd quarter. Allworth Financial LP now owns 1,145 shares of the company’s stock worth $57,000 after acquiring an additional 616 shares during the period. IFP Advisors Inc lifted its position in Heartflow by 844.7% during the 3rd quarter. IFP Advisors Inc now owns 803 shares of the company’s stock worth $40,000 after acquiring an additional 718 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in Heartflow during the 2nd quarter worth $53,000. Finally, Mayport LLC boosted its holdings in Heartflow by 20.0% during the second quarter. Mayport LLC now owns 12,000 shares of the company’s stock valued at $352,000 after acquiring an additional 2,000 shares during the period.

More Heartflow News

Investors following HTFL have been watching these news items:

• Positive Sentiment: Third-quarter revenue rose 57% year over year to $72.9 million, exceeding the roughly $65.2 million analyst estimate. The loss was $0.03 per share, narrower than both the expected $0.18 loss and the $0.27 loss a year earlier. HeartFlow Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Heartflow raised its 2026 revenue guidance to $262 million–$264 million, above the approximately $248.6 million consensus estimate. The higher outlook may signal stronger growth expectations. Heartflow Expects 2026 Revenue of $262M–$264M
• Negative Sentiment: CEO insider selling may weigh on sentiment: the CEO sold $2.17 million of Heartflow stock. A sale by itself does not establish the reason for the transaction. Heartflow CEO Sells $2.17 Million in Stock

Heartflow Company Profile

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.